Michael E Weinblatt Selected Research

Methotrexate (Mexate)

5/2022	Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
1/2022	Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
12/2021	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
8/2021	Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study.
6/2021	Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate.
4/2021	Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis.
1/2021	Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
12/2019	The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study.
3/2019	Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis.
1/2019	Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael E Weinblatt Research Topics

Disease

121	Rheumatoid Arthritis 05/2022 - 03/2002
17	Infections 08/2021 - 11/2003
7	Rheumatic Diseases (Rheumatism) 08/2021 - 03/2009
7	Arthritis (Polyarthritis) 01/2019 - 05/2002
6	Fatigue 01/2022 - 04/2013
6	Inflammation (Inflammations) 01/2019 - 01/2010
5	Pain (Aches) 01/2022 - 04/2013
4	Heart Failure 01/2021 - 08/2008
4	Neoplasms (Cancer) 01/2017 - 05/2006
3	Venous Thromboembolism 12/2021 - 01/2019
3	Psoriatic Arthritis 11/2018 - 04/2003
3	Disease Progression 01/2018 - 05/2004
3	Injection Site Reaction 08/2015 - 01/2013
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2021 - 01/2021
2	Liver Diseases (Liver Disease) 01/2021 - 01/2021
2	Lung Diseases (Lung Disease) 01/2021 - 01/2021
2	Rheumatoid Nodule 01/2021 - 01/2019
2	Necrosis 01/2020 - 11/2018
2	Dyspnea (Shortness of Breath) 03/2019 - 07/2014
2	Hypersensitivity (Allergy) 11/2018 - 11/2018
2	Myositis (Idiopathic Inflammatory Myopathies) 08/2008 - 05/2006
1	COVID-19 06/2022
1	Skin Neoplasms (Skin Cancer) 05/2022
1	Melanoma (Melanoma, Malignant) 05/2022
1	Emphysema 01/2022
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2022
1	Cardiac Arrhythmias (Arrythmia) 01/2022
1	Myocardial Infarction 01/2022
1	Gout 01/2021
1	Herpes Zoster 06/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 08/2019
1	Pulmonary Embolism 01/2019
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019
1	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2018

Drug/Important Bio-Agent (IBA)

46	Methotrexate (Mexate)FDA LinkGeneric 05/2022 - 03/2002
21	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 01/2003
17	Antirheumatic Agents (DMARD)IBA 05/2022 - 05/2004
17	brassIBA 01/2022 - 01/2006
15	Adalimumab (Humira)FDA Link 04/2022 - 01/2003
13	Biological ProductsIBA 01/2021 - 09/2006
10	Etanercept (Enbrel)FDA Link 01/2020 - 05/2002
9	Pharmaceutical PreparationsIBA 08/2021 - 05/2004
9	Monoclonal AntibodiesIBA 01/2018 - 01/2003
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
8	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 09/2008
7	C-Reactive ProteinIBA 01/2021 - 02/2011
7	Rheumatoid FactorIBA 01/2020 - 01/2008
6	Abatacept (Orencia)FDA Link 04/2022 - 01/2013
6	GlucocorticoidsIBA 01/2021 - 06/2007
6	fostamatinibIBA 01/2018 - 02/2011
6	Syk KinaseIBA 12/2014 - 11/2008
5	Anti-Citrullinated Protein AntibodiesIBA 04/2022 - 05/2009
5	AutoantibodiesIBA 01/2020 - 10/2008
5	Infliximab (Remicade)FDA Link 01/2020 - 12/2005
4	Biosimilar PharmaceuticalsIBA 01/2020 - 01/2018
4	golimumab FDA Link 01/2018 - 03/2013
4	Certolizumab Pegol FDA Link 10/2017 - 12/2012
3	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 05/2022 - 12/2021
3	cyclic citrullinated peptideIBA 01/2022 - 05/2009
3	tofacitinibIBA 12/2021 - 06/2018
3	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2019 - 06/2003
3	baricitinibIBA 01/2019 - 01/2017
3	Interleukin-17 (Interleukin 17)IBA 11/2018 - 11/2018
3	mavrilimumabIBA 01/2018 - 09/2013
2	EpitopesIBA 04/2022 - 10/2010
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2019
2	AntibodiesIBA 01/2021 - 04/2003
2	Peptides (Polypeptides)IBA 01/2021 - 03/2012
2	Collagen Type I (Type I Collagen)IBA 01/2019 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2012
2	ABT-122IBA 11/2018 - 11/2018
2	CollagenIBA 01/2018 - 01/2010
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2018 - 09/2013
2	ametantrone (HAQ)IBA 11/2017 - 04/2015
2	HDL LipoproteinsIBA 12/2016 - 01/2015
2	HDL CholesterolIBA 12/2016 - 01/2015
2	LDL Lipoproteins (beta Lipoproteins)IBA 12/2016 - 01/2015
2	LDL CholesterolIBA 12/2016 - 01/2015
2	3-benzoyl dopamine (MBDA)IBA 04/2016 - 01/2013
2	LipidsIBA 01/2015 - 05/2010
2	tocilizumab (atlizumab)FDA Link 03/2013 - 07/2011
2	Immunoglobulin G (IgG)IBA 03/2012 - 08/2010
2	CytokinesIBA 04/2011 - 06/2003
2	EnzymesIBA 05/2010 - 04/2003
2	Rituximab (Mabthera)FDA Link 08/2008 - 05/2006
1	COVID-19 VaccinesIBA 06/2022
1	ORALIT (ORS)IBA 06/2022
1	acetyl 4-aminosalicylic acidIBA 04/2022
1	Pegloticase FDA Link 01/2021
1	Synthetic Vaccines (Recombinant Vaccines)IBA 06/2020
1	Herpes Zoster VaccineIBA 06/2020
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 08/2019
1	Type II Tumor Necrosis Factor ReceptorsIBA 08/2019
1	amsonic acid (DAS)IBA 11/2018
1	Janus Kinase InhibitorsIBA 06/2018

Therapy/Procedure

28	Therapeutics 01/2020 - 05/2002
3	Biological Therapy 11/2019 - 02/2011
2	Ambulatory Care (Outpatient Care) 01/2013 - 04/2002